Reply

Corinne Keet; Wayne Shreffler; Robert Wood; Alkis Togias; Michael Pistiner

doi:10.1016/j.jaci.2021.03.013

Reply

Corinne Keet, Wayne Shreffler, Robert Wood, Alkis Togias, Michael Pistiner

School of Medicine

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	273
Number of pages	1
Journal	Journal of Allergy and Clinical Immunology
Volume	148
Issue number	1
DOIs	https://doi.org/10.1016/j.jaci.2021.03.013
State	Published - Jul 2021

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1016/j.jaci.2021.03.013

Cite this

@article{6f478a76d86d4096b84b2c7d4289c27a,

title = "Reply",

author = "Corinne Keet and Wayne Shreffler and Robert Wood and Alkis Togias and Michael Pistiner",

note = "Funding Information: Disclosure of potential conflict of interest: C. Keet receives royalties from Up to Date. W. Shreffler has served on the Scientific Advisory Board of Aimmune Therapeutics, and as an advisor to Food Allergy Research & Education (FARE), Buhlmann Laboratories AG, and Sanofi Pasteur. R. Wood receives research support from FARE, Aimmune, DBV, Astellas, Regeneron, Sanofi, and HAL-Allergy, and royalties from Up to Date. A. Togias reports no relevant conflicts of interest. M. Pistiner has served as a consultant for Asthma and Allergy Foundation of America, kal{\'e}o, and DBV Technologies; received funding from kal{\'e}o, DBV Technologies, and the National Peanut Board; and is cofounder of AllergyHome and Allergy Certified Training. Funding Information: This study was funded by the National Institutes of Health (NIH)/ National Institute of Allergy and Infectious Diseases (grant no. 1U01AI125290 ). This publication was made possible by the Johns Hopkins Institute for Clinical and Translational Research (ICTR), which is funded in part by the National Center for Advancing Translational Sciences (NCATS) (grant no. UL1 TR003098 ), a component of the NIH , and NIH Roadmap for Medical Research . Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the Johns Hopkins ICTR, NCATS, or NIH. The project described was supported by grant number 1UL1TR002541-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources, the NCATS, or the NIH. Funding Information: This study was funded by the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (grant no. 1U01AI125290). This publication was made possible by the Johns Hopkins Institute for Clinical and Translational Research (ICTR), which is funded in part by the National Center for Advancing Translational Sciences (NCATS) (grant no. UL1 TR003098), a component of the NIH, and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the Johns Hopkins ICTR, NCATS, or NIH. The project described was supported by grant number 1UL1TR002541-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources, the NCATS, or the NIH. Disclosure of potential conflict of interest: C. Keet receives royalties from Up to Date. W. Shreffler has served on the Scientific Advisory Board of Aimmune Therapeutics, and as an advisor to Food Allergy Research & Education (FARE), Buhlmann Laboratories AG, and Sanofi Pasteur. R. Wood receives research support from FARE, Aimmune, DBV, Astellas, Regeneron, Sanofi, and HAL-Allergy, and royalties from Up to Date. A. Togias reports no relevant conflicts of interest. M. Pistiner has served as a consultant for Asthma and Allergy Foundation of America, kal?o, and DBV Technologies; received funding from kal?o, DBV Technologies, and the National Peanut Board; and is cofounder of AllergyHome and Allergy Certified Training.",

year = "2021",

month = jul,

doi = "10.1016/j.jaci.2021.03.013",

language = "English (US)",

volume = "148",

pages = "273",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Mosby Inc.",

number = "1",

}

TY - JOUR

T1 - Reply

AU - Keet, Corinne

AU - Shreffler, Wayne

AU - Wood, Robert

AU - Togias, Alkis

AU - Pistiner, Michael

N1 - Funding Information: Disclosure of potential conflict of interest: C. Keet receives royalties from Up to Date. W. Shreffler has served on the Scientific Advisory Board of Aimmune Therapeutics, and as an advisor to Food Allergy Research & Education (FARE), Buhlmann Laboratories AG, and Sanofi Pasteur. R. Wood receives research support from FARE, Aimmune, DBV, Astellas, Regeneron, Sanofi, and HAL-Allergy, and royalties from Up to Date. A. Togias reports no relevant conflicts of interest. M. Pistiner has served as a consultant for Asthma and Allergy Foundation of America, kaléo, and DBV Technologies; received funding from kaléo, DBV Technologies, and the National Peanut Board; and is cofounder of AllergyHome and Allergy Certified Training. Funding Information: This study was funded by the National Institutes of Health (NIH)/ National Institute of Allergy and Infectious Diseases (grant no. 1U01AI125290 ). This publication was made possible by the Johns Hopkins Institute for Clinical and Translational Research (ICTR), which is funded in part by the National Center for Advancing Translational Sciences (NCATS) (grant no. UL1 TR003098 ), a component of the NIH , and NIH Roadmap for Medical Research . Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the Johns Hopkins ICTR, NCATS, or NIH. The project described was supported by grant number 1UL1TR002541-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources, the NCATS, or the NIH. Funding Information: This study was funded by the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (grant no. 1U01AI125290). This publication was made possible by the Johns Hopkins Institute for Clinical and Translational Research (ICTR), which is funded in part by the National Center for Advancing Translational Sciences (NCATS) (grant no. UL1 TR003098), a component of the NIH, and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the Johns Hopkins ICTR, NCATS, or NIH. The project described was supported by grant number 1UL1TR002541-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources, the NCATS, or the NIH. Disclosure of potential conflict of interest: C. Keet receives royalties from Up to Date. W. Shreffler has served on the Scientific Advisory Board of Aimmune Therapeutics, and as an advisor to Food Allergy Research & Education (FARE), Buhlmann Laboratories AG, and Sanofi Pasteur. R. Wood receives research support from FARE, Aimmune, DBV, Astellas, Regeneron, Sanofi, and HAL-Allergy, and royalties from Up to Date. A. Togias reports no relevant conflicts of interest. M. Pistiner has served as a consultant for Asthma and Allergy Foundation of America, kal?o, and DBV Technologies; received funding from kal?o, DBV Technologies, and the National Peanut Board; and is cofounder of AllergyHome and Allergy Certified Training.

PY - 2021/7

Y1 - 2021/7

UR - http://www.scopus.com/inward/record.url?scp=85106983547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85106983547&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2021.03.013

DO - 10.1016/j.jaci.2021.03.013

M3 - Letter

C2 - 33926728

AN - SCOPUS:85106983547

VL - 148

SP - 273

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 1

ER -

Reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this